Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.59 |
| ▸ | LAP3 | P28838 | 2/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472188 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL2339158 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL5575815 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL9487038 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL9841018 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL2023917 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL30595172 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL3377184 | 1.00 | FDPS (0.59) | FDPSLAP3GPR84FOLH1FFAR1 | |
| Butane SCHEMBL2906335 | 0.98 | FDPS (0.57) | FDPSLAP3GPR84FOLH1FFAR1 | |
| SCHEMBL389804 | 0.98 | FDPS (0.57) | FDPSLAP3GPR84FOLH1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125029-B1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | MDRNA RESEARCH, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2004029582-A2 | SURFACE PLASMON RESONANCE SYSTEMS AND METHODS HAVING A VARIABLE CHARGE DENSITY LAYER | NORTH CAROLINA STATE UNIVERSITY (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | FDPS 3321/4885LAP3 1681/4885GPR84 3273/4885 |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | FDPS 3321/4885LAP3 1681/4885GPR84 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.